Clinical Research Directory

Inclusion Criteria: * Age 2 to 17 years * American Society of Anesthesiologists (ASA) physical status I * Elective adenoidectomy or adenotonsillectomy under general anesthesia maintained with sevoflurane * Neuromuscular blockade with rocuronium 0.6 milligrams per kilogram (mg/kg) * Sugammadex 4 mg/kg administered at least 60 minutes after rocuronium * Planned extubation in the operating room * Written informed consent from a parent or legal guardian Exclusion Criteria: * ASA physical status II or higher * Neuromuscular disease (e.g., myasthenia gravis, muscular dystrophy) * History of hepatic or renal dysfunction * Regular use of drugs affecting neuromuscular transmission (e.g., steroids, aminoglycosides, magnesium) * History of prematurity (less than 37 weeks of gestation) * Morbid obesity (body mass index \[BMI\] above the 95th percentile for age and sex) * Serious cardiac, pulmonary or neurological disease * Known allergy or hypersensitivity, particularly to sugammadex or rocuronium * End-tidal sevoflurane minimum alveolar concentration (MAC) at the time of sugammadex administration outside the defined cohort ranges * Unplanned intraoperative events (e.g., major bleeding, prolonged surgery, need for additional drugs) * Refusal of consent by a parent or legal guardian